Even the smallest injection delivers 25 mcg, which is over 1,000% of the daily value
In the STEP2 focusing on 1,210 patients with obesity or overweight and T2D, average weight loss with semaglutide 2.4 mg therapy was 6.2% compared to the placebo [47]
Semax and Selank are approved as finished drugs in Russia but not in Canada, the United States, or the EU, and Dihexa and P21 are not approved as finished drugs anywhere
Regulatory agencies require extensive clinical evidence before approval, and the absence of such data means safety and effectiveness remain uncertain
TH17 cells release IL-17 and IL-22, which activate keratinocytes
Side Effects and Safety Considerations Both peptides have relatively favorable safety profiles based on existing research and clinical use in Russia over several decades